問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Digestive System Department

Division of General Internal Medicine

Division of General Surgery

Far Eastern Memorial Hospital (非在職)

Division of Hematology & Oncology

更新時間：2025-02-26

葉坤輝Yeh, Kun-Huei
  • Principal Investigator
  • Clinical Trial Experience (year) -24 years -4 個月

Recruiting Trial

97Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

葉坤輝

List

204Cases

2021-06-01 - 2022-04-20

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Not yet recruiting1Sites

2015-09-15 - 2019-09-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Terminated11Sites

林振源
China Medical University Hospital-Taipei

未分科

2018-10-01 - 2021-03-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting3Sites

Terminated1Sites

白禮源
China Medical University Hospital-Taipei

未分科

2024-11-01 - 2028-09-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

2023-08-01 - 2027-04-01

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2016-02-12 - 2018-01-15

Phase I/II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
1Sites

Terminated1Sites

2021-03-01 - 2023-04-15

Phase II

A Phase II, Randomized, Double-Blind Placebo-Controlled Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer

  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    Atezolizumab(TecentriqR) Bevacizumab(AvastinR)

Participate Sites
3Sites

Terminated3Sites

2012-10-01 - 2017-12-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2012-09-01 - 2017-08-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2013-03-01 - 2020-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

1 12 13 14 15 16 21
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB